Morfina Serra Ip (Morphine Hydrochloride)

Morphine hydrochloride binds to μ‑opioid receptors in the brain and spinal cord, activating G‑protein pathways that inhibit neuronal firing and reduce the release of pain‑transmitting neurotransmitters. This results in decreased perception of pain and a calming, sedative effect.

The dose of Morfina Serra Ip is individualized. A qualified prescriber determines the appropriate amount, route, and frequency based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and overall clinical condition.

Data on morphine use during pregnancy and lactation are limited. It should be used only when the expected benefit to the mother outweighs potential risks to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Morphine is a prototypical μ‑opioid receptor agonist with high potency and a well‑characterised safety profile. Compared with weaker opioids such as codeine, morphine provides stronger analgesia but also carries a higher risk of respiratory depression and dependence, requiring careful dosing and monitoring.

Store the product below 25 °C in its original packaging, protected from light and moisture. Keep the vial or ampoule sealed until use, and follow aseptic technique when preparing for epidural, intrathecal or intravenous administration.

Morfina Serra Ip is supplied as a sterile injectable solution for epidural, intrathecal or intravenous injection. Administration must be performed by qualified healthcare professionals using aseptic technique, with dosing adjusted to the patient’s response and monitored for efficacy and safety.

The most serious risks include respiratory depression, severe hypotension, profound sedation, and the potential for opioid dependence or abuse. Immediate medical attention is required if signs of respiratory compromise, extreme drowsiness, or allergic reaction occur.

Patients with known hypersensitivity to morphine or other opioids, those with severe respiratory insufficiency, acute asthma attacks, or uncontrolled increased intracranial pressure should avoid this medication. It is also contraindicated in individuals taking MAO inhibitors within the past 14 days.